Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578634 | 1.00 | HDAC1 (0.69) | HDAC1HDAC3HDAC2KCNH2HDAC8 | |
| SCHEMBL4578949 | 0.87 | HDAC1 (0.58) | HDAC1HDAC3HDAC2KCNH2HDAC8 | |
| SCHEMBL4578946 | 0.87 | HDAC1 (0.58) | HDAC1HDAC3HDAC2KCNH2HDAC8 | |
| SCHEMBL14155980 | 0.84 | HDAC1 (0.71) | HDAC1HDAC3HDAC2KCNH2HDAC8 | |
| SCHEMBL210231 | 0.83 | HDAC1 (0.53) | HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL210919 | 0.83 | HDAC1 (0.53) | HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL210232 | 0.83 | HDAC1 (0.53) | HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL17832678 | 0.82 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL4580351 | 0.82 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL4580347 | 0.82 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466670-B | Inhibitors of histone deacetylase | METHYLGENE INC | 2013-04-17 | — | — | CN | claimed |
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| CN-101466670-B | Inhibitors of histone deacetylase | METHYLGENE INC | 2013-04-17 | — | — | CN | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.